| Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018 JM Loree, S Anand, A Dasari, JM Unger, A Gothwal, LM Ellis, ... JAMA oncology 5 (10), e191870-e191870, 2019 | 406 | 2019 |
| Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes JM Loree, AAL Pereira, M Lam, AN Willauer, K Raghav, A Dasari, ... Clinical Cancer Research 24 (5), 1062-1072, 2018 | 313 | 2018 |
| Clinical and molecular characterization of early‐onset colorectal cancer AN Willauer, Y Liu, AAL Pereira, M Lam, JS Morris, KPS Raghav, ... Cancer 125 (12), 2002-2010, 2019 | 275 | 2019 |
| Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: the Canadian Cancer Trials Group CO. 26 Study EX Chen, DJ Jonker, JM Loree, HF Kennecke, SR Berry, F Couture, ... JAMA oncology 6 (6), 831-838, 2020 | 269 | 2020 |
| Irradiation induces DNA damage and modulates epigenetic effectors in distant bystander tissue in vivo I Koturbash, RE Rugo, CA Hendricks, J Loree, B Thibault, K Kutanzi, ... Oncogene 25 (31), 4267-4275, 2006 | 267 | 2006 |
| Genomic landscape of cell-free DNA in patients with colorectal cancer JH Strickler, JM Loree, LG Ahronian, AR Parikh, D Niedzwiecki, ... Cancer discovery 8 (2), 164-173, 2018 | 257* | 2018 |
| Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge CM Parseghian, JM Loree, VK Morris, X Liu, KK Clifton, S Napolitano, ... Annals of Oncology 30 (2), 243-249, 2019 | 213 | 2019 |
| Platelet “first responders” in wound response, cancer, and metastasis DG Menter, S Kopetz, E Hawk, AK Sood, JM Loree, P Gresele, KV Honn Cancer and Metastasis Reviews 36, 199-213, 2017 | 179 | 2017 |
| Epigenetic dysregulation underlies radiation-induced transgenerational genome instability in vivo I Koturbash, M Baker, J Loree, K Kutanzi, D Hudson, I Pogribny, ... International Journal of Radiation Oncology* Biology* Physics 66 (2), 327-330, 2006 | 150 | 2006 |
| In vivo bystander effect: cranial X-irradiation leads to elevated DNA damage, altered cellular proliferation and apoptosis, and increased p53 levels in shielded spleen I Koturbash, J Loree, K Kutanzi, C Koganow, I Pogribny, O Kovalchuk International Journal of Radiation Oncology* Biology* Physics 70 (2), 554-562, 2008 | 137 | 2008 |
| Deleterious effect of RAS and evolutionary high-risk TP53 double mutation in colorectal liver metastases YS Chun, G Passot, S Yamashita, M Nusrat, P Katsonis, JM Loree, ... Annals of surgery 269 (5), 917-923, 2019 | 134 | 2019 |
| Trends in the epidemiology of young-onset colorectal cancer: a worldwide systematic review K Saad El Din, JM Loree, EC Sayre, S Gill, CJ Brown, H Dau, MA De Vera BMC cancer 20, 1-14, 2020 | 125 | 2020 |
| Recent developments in the treatment of metastatic colorectal cancer JM Loree, S Kopetz Therapeutic advances in medical oncology 9 (8), 551-564, 2017 | 120 | 2017 |
| Using circulating tumor DNA in colorectal cancer: current and evolving practices M Malla, JM Loree, PM Kasi, AR Parikh Journal of Clinical Oncology 40 (24), 2846, 2022 | 97 | 2022 |
| Radiation-induced molecular changes in rat mammary tissue: possible implications for radiation-induced carcinogenesis J Loree, I Koturbash, K Kutanzi, M Baker, I Pogribny, O Kovalchuk International journal of radiation biology 82 (11), 805-815, 2006 | 94 | 2006 |
| Mechanisms of innate and acquired resistance to anti-EGFR therapy: a review of current knowledge with a focus on rechallenge therapies CM Parseghian, S Napolitano, JM Loree, S Kopetz Clinical Cancer Research 25 (23), 6899-6908, 2019 | 92 | 2019 |
| Circulating DNA demonstrates convergent evolution and common resistance mechanisms during treatment of colorectal cancer AR Thierry, B Pastor, ZQ Jiang, AD Katsiampoura, C Parseghian, ... Clinical Cancer Research 23 (16), 4578-4591, 2017 | 89 | 2017 |
| The CCTG PA. 7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma DJ Renouf, JM Loree, JJ Knox, JT Topham, P Kavan, D Jonker, S Welch, ... Nature communications 13 (1), 5020, 2022 | 88* | 2022 |
| High mortality among hospital-acquired COVID-19 infection in patients with cancer: a multicentre observational cohort study A Elkrief, A Desilets, N Papneja, L Cvetkovic, C Groleau, YA Lakehal, ... European Journal of Cancer 139, 181-187, 2020 | 82 | 2020 |
| Validation of HER2 Amplification as a Predictive Biomarker for Anti–Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer K Raghav, JM Loree, JS Morris, MJ Overman, R Yu, F Meric-Bernstam, ... JCO Precision Oncology 3, 1-13, 2019 | 79 | 2019 |
Scott KopetzUniversity of Texas MD Anderson Cancer CenterVerified email at mdanderson.org
